ATE326963T1 - Indolverbindungen als spla2 inhibitoren - Google Patents
Indolverbindungen als spla2 inhibitorenInfo
- Publication number
- ATE326963T1 ATE326963T1 AT99938936T AT99938936T ATE326963T1 AT E326963 T1 ATE326963 T1 AT E326963T1 AT 99938936 T AT99938936 T AT 99938936T AT 99938936 T AT99938936 T AT 99938936T AT E326963 T1 ATE326963 T1 AT E326963T1
- Authority
- AT
- Austria
- Prior art keywords
- indole compounds
- spla2 inhibitors
- compounds
- spla2
- inhibitors
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 abstract 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9511498P | 1998-08-03 | 1998-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE326963T1 true ATE326963T1 (de) | 2006-06-15 |
Family
ID=22249768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99938936T ATE326963T1 (de) | 1998-08-03 | 1999-08-02 | Indolverbindungen als spla2 inhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6451839B1 (enExample) |
| EP (1) | EP1100492B1 (enExample) |
| JP (1) | JP2002522385A (enExample) |
| AT (1) | ATE326963T1 (enExample) |
| CA (1) | CA2338855A1 (enExample) |
| DE (1) | DE69931496T2 (enExample) |
| ES (1) | ES2263283T3 (enExample) |
| WO (1) | WO2000007590A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1100493A4 (en) * | 1998-08-03 | 2001-10-24 | Lilly Co Eli | SPLA 2 INHIBITORS? OF THE INDOLTYPS |
| EP1303262A2 (en) * | 2000-07-14 | 2003-04-23 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
| ATE329905T1 (de) * | 2000-12-18 | 2006-07-15 | Lilly Co Eli | Tetracyclische derivate als spla2 inhibitoren |
| US6992100B2 (en) | 2001-12-06 | 2006-01-31 | Eli Lilly And Company | sPLA2 inhibitors |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| DE602004023062D1 (en) * | 2003-03-31 | 2009-10-22 | Lilly Co Eli | 3-oxo-1,3-dihydro-indazol-2-carbonsäureamid derivate als phospholipase inhibitoren |
| WO2005107767A2 (en) * | 2004-05-03 | 2005-11-17 | Ilypsa, Inc. | Modulation of lysophosphatidylcholine and treatment of diet-induced conditions |
| WO2007056280A1 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors |
| WO2007056279A2 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
| JP2009517341A (ja) * | 2005-11-03 | 2009-04-30 | イリプサ， インコーポレイテッド | Ｃ４−アミド置換基を有するインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用 |
| AU2006311851A1 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Azaindole compounds and use thereof as phospholipase-A2 inhibitors |
| WO2007056281A2 (en) * | 2005-11-03 | 2007-05-18 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors |
| EP2211425A1 (en) | 2009-01-23 | 2010-07-28 | MTA S.p.A. | Female electrical terminal |
| EP4008327A1 (en) | 2009-04-29 | 2022-06-08 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5312928A (en) | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
| US5132319A (en) * | 1991-03-28 | 1992-07-21 | Merck Frosst Canada, Inc. | 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis |
| GB9204365D0 (en) | 1992-02-28 | 1992-04-08 | Pfizer Ltd | Indoles |
| DE69217087T2 (de) | 1992-11-27 | 1997-07-10 | Yason Srl | Indolderivat mit verlängerter immunostimmulierender wirkung und pharmazeutische zusammensetzungen daraus |
| IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| IL109311A0 (en) | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| US6252084B1 (en) * | 1994-03-15 | 2001-06-26 | Eli Lilly And Company | 1H-indole-3-acetamide sPLA2 inhibitors |
| ATE220394T1 (de) * | 1994-04-01 | 2002-07-15 | Lilly Co Eli | 1h-indol-3-glyoxylamid spla2 inhibitoren |
| CA2310249A1 (en) * | 1997-11-14 | 1999-05-27 | August Masaru Watanabe | Treatment for alzheimer's disease |
-
1999
- 1999-08-02 CA CA002338855A patent/CA2338855A1/en not_active Abandoned
- 1999-08-02 AT AT99938936T patent/ATE326963T1/de not_active IP Right Cessation
- 1999-08-02 EP EP99938936A patent/EP1100492B1/en not_active Expired - Lifetime
- 1999-08-02 DE DE69931496T patent/DE69931496T2/de not_active Expired - Fee Related
- 1999-08-02 JP JP2000563275A patent/JP2002522385A/ja not_active Withdrawn
- 1999-08-02 US US09/762,069 patent/US6451839B1/en not_active Expired - Fee Related
- 1999-08-02 ES ES99938936T patent/ES2263283T3/es not_active Expired - Lifetime
- 1999-08-02 WO PCT/US1999/017459 patent/WO2000007590A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US6451839B1 (en) | 2002-09-17 |
| EP1100492A1 (en) | 2001-05-23 |
| DE69931496D1 (de) | 2006-06-29 |
| WO2000007590A1 (en) | 2000-02-17 |
| EP1100492A4 (en) | 2001-10-24 |
| ES2263283T3 (es) | 2006-12-01 |
| DE69931496T2 (de) | 2006-11-23 |
| EP1100492B1 (en) | 2006-05-24 |
| JP2002522385A (ja) | 2002-07-23 |
| CA2338855A1 (en) | 2000-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69527322D1 (de) | 1H-Indol-3-Glyoxylamid sPLA2 Inhibitoren | |
| DE69724009D1 (de) | PYRROLE ALS sPLA2 INHIBITOREN | |
| ATE326963T1 (de) | Indolverbindungen als spla2 inhibitoren | |
| ATE203744T1 (de) | Naphthyl-acetamide als spla2-inhibitoren | |
| DE69720034D1 (de) | PHENYLGLYOXAMIDE ALS sPLA2-INHIBITOREN | |
| ATE350367T1 (de) | Spla2 inhibitoren | |
| ATE312817T1 (de) | Cyclohept'bö indolderivate als spla2-inhibitoren | |
| DE69910432D1 (de) | Substituierte pyrroloindole | |
| WO2002012249A3 (en) | Substituted pyrrole compounds and their use as spla2 inhibitors | |
| DE60032254D1 (de) | Hydroxyfunktionelle amid-1h-indolderivate aktiv als spla2 inhibitoren | |
| DE60126831D1 (de) | Benz(g)indole und deren verwendung als spla2 inhibitoren | |
| WO2002050028A3 (en) | Substituted benzoindoles as spla2 inhibitors | |
| WO2001049662A3 (en) | Carbazole derivatives as inhibitors of spla2 | |
| ATE329905T1 (de) | Tetracyclische derivate als spla2 inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |